Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
33589755
PubMed Central
PMC8324471
DOI
10.1038/s41375-021-01173-w
PII: 10.1038/s41375-021-01173-w
Knihovny.cz E-resources
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Time Factors MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy genetics pathology MeSH
- Remission Induction MeSH
- Protein Kinase Inhibitors adverse effects MeSH
- Clinical Trials as Topic methods MeSH
- Humans MeSH
- Neoplasm Recurrence, Local chemically induced diagnosis epidemiology MeSH
- Withholding Treatment statistics & numerical data MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe epidemiology MeSH
- Names of Substances
- Fusion Proteins, bcr-abl MeSH
- Protein Kinase Inhibitors MeSH
Department of Hematology Karolinska University Hospital Stockholm Sweden
Department of Hematology Oncology and Radiation Physics Skåne University Hospital Lund Sweden
Department of Hematology St Olavs Hospital Trondheim Norway
Department of Hematology Sunderby Hospital Luleå Sweden
Department of Hematology University Hospital Linköping Sweden
Department of Hematology University Hospital Umeå Sweden
Department of Medicine Faculty of Medicine and Health Örebro University Örebro Sweden
Department of Medicine Karolinska University Hospital Stockholm Sweden
Department of Public Health and Clinical Medicine Umeå University Umeå Sweden
See more in PubMed
Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;3:452–68. doi: 10.1111/bjh.16408. PubMed DOI
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;6:747–57. doi: 10.1016/S1470-2045(18)30192-X. PubMed DOI
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;5:424–30. doi: 10.1200/JCO.2012.48.5797. PubMed DOI
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;3:298–305. doi: 10.1200/JCO.2016.68.2914. PubMed DOI
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. doi: 10.1016/S1470-2045(10)70233-3. PubMed DOI
Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2010;13:3034–40. PubMed PMC
Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;8:1589–96. doi: 10.3324/haematol.2018.205054. PubMed DOI PMC
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. doi: 10.1038/s41375-020-0776-2. PubMed DOI PMC
